TY - JOUR
T1 - Use of adjuvants for immunotherapy
AU - Circelli, Luisa
AU - Tornesello, Marialina
AU - Buonaguro, Franco M.
AU - Buonaguro, Luigi
PY - 2017/8
Y1 - 2017/8
N2 - Cancer vaccines are designed to stimulate the body's immune system to kill tumor cells. To improve their immunogenicity, vaccine antigens must be combined with adjuvants which are able to stimulate the innate immunity and potentiate the adaptive immune response. In the last years a new generation of adjuvants mimicking the natural microbial ligands have been developed. In particular, several TLR ligands have been extensively explored as vaccine adjuvants and many preclinical and clinical studies have been conducted. However, the road to approval of such adjuvants for clinical use is still to go.
AB - Cancer vaccines are designed to stimulate the body's immune system to kill tumor cells. To improve their immunogenicity, vaccine antigens must be combined with adjuvants which are able to stimulate the innate immunity and potentiate the adaptive immune response. In the last years a new generation of adjuvants mimicking the natural microbial ligands have been developed. In particular, several TLR ligands have been extensively explored as vaccine adjuvants and many preclinical and clinical studies have been conducted. However, the road to approval of such adjuvants for clinical use is still to go.
KW - adjuvant
KW - cancer immunotherapy
KW - cancer vaccine
KW - Toll-like receptors
UR - http://www.scopus.com/inward/record.url?scp=85020513208&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85020513208&partnerID=8YFLogxK
U2 - 10.1080/21645515.2017.1321725
DO - 10.1080/21645515.2017.1321725
M3 - Article
AN - SCOPUS:85020513208
SP - 1
EP - 4
JO - Human Vaccines and Immunotherapeutics
JF - Human Vaccines and Immunotherapeutics
SN - 2164-5515
ER -